




§Appl. No. 10/575,027
 Amdt. dated June 25, 2010
 Reply to Office Action of, January 5, 2010


Claims:

1. (Currently Amended) A compound of the ~~Formula~~ Formulae (A), II or III their tautomeric and stereoisomeric form, and salts thereof:



wherein

A represents the formula



wherein

represents the connection position to the molecule,
Q₁ and Q₄ (~~Chapter I~~) independently represent direct bond or methylene;
Chemical bond between Q₂ ---- Q₃ (~~Chapter I~~) is selected from the group consisting of a single bond and a double bond;
when Q₂ ---- Q₃ (~~Chapter I~~) is a single bond, Q₂ (~~Chapter I~~) represents CHR², or CO, and Q₃ (~~Chapter I~~) represents CHR³,
when Q₂ ---- Q₃ (~~Chapter I~~) is a double bond, Q₂ (~~Chapter I~~) represents CR² and Q₃ (~~Chapter I~~) represents CR³;

wherein

R² (~~Chapter I~~) represents hydrogen, hydroxy, C₁₋₆ alkoxy or C₁₋₆ alkanoyloxy;

R³ (~~Chapter I~~) represents hydrogen, hydroxy, C₁₋₆ alkanoyloxy, or C₁₋₆ alkyl optionally substituted by hydroxy, C₁₋₆ alkoxy or C₁₋₆ alkanoyloxy, with the proviso that Q₁ and Q₄ (~~Chapter I~~) cannot be direct bond at the same time;

R² and R³ (~~Chapter I~~) cannot be hydrogen at the same time;

when Q₁ and Q₂ (~~Chapter I~~) are both methylene and R³ (~~Chapter I~~) is hydroxy, R² (~~Chapter I~~) is hydroxy, C₁₋₆ alkoxy or C₁₋₆ alkanoyloxy;

when Q₁ (~~Chapter I~~) is direct bond, R² (~~Chapter I~~) is hydroxy, C₁₋₆ alkoxy or C₁₋₆ alkanoyloxy; and when Q₄ (~~Chapter I~~) is direct bond, R² (~~Chapter I~~) is hydrogen C₁₋₆ alkoxy or C₁₋₆ alkanoyloxy;

Q₁, Q₂ ---- (~~Chapter IV~~) independently represent N or CH,

phenoxy optionally substituted by halogen or C₁₋₆ alkyl, and C₁₋₆ alkylthio optionally substituted by mono-, di-, or tri- halogen.

$R^+R_{II}^I$ (~~Chapter II~~) represents C₃₋₈ cycloalkyl optionally fused by aryl

wherein

said aryl is optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, carboxy, nitro, cyano, amino, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, C₁₋₆ alkyl optionally substituted by cyano, C₁₋₆ alkoxycarbonyl, or mono-, di-, or tri-halogen, C₁₋₆ alkoxy optionally substituted by mono-, di-, or tri-halogen and C₁₋₆ alkylthio optionally substituted by mono-, di-, or tri- halogen;

phenyl, substituted by heteroaryl, or heteroaryloxy,

wherein

said heteroaryl and heteroaryloxy are optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, carboxy, nitro, cyano, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, C₁₋₆ alkyl optionally substituted by cyano, C₁₋₆ alkoxycarbonyl, or mono-, di-, or tri-halogen, C₁₋₆ alkoxy optionally substituted by mono-, di-, or tri- halogen, and C₁₋₆ alkylthio optionally substituted by mono-, di-, or tri- halogen;

phenyl fused with heteroaryl, or heterocyclyl,

wherein

§Appl. No. 10/575,027
Amdt. dated June 25, 2010
Reply to Office Action of, January 5, 2010

said heteroaryl is optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, carboxy, nitro, cyano, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₁₋₆ alkoxy carbonyl, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, C₁₋₆ alkyl optionally substituted by cyano, C₁₋₆ alkoxy carbonyl, or mono-, di-, or tri-halogen, C₁₋₆ alkoxy optionally substituted by mono-, di-, or tri- halogen, and C₁₋₆ alkylthio optionally substituted by mono-, di-, or tri- halogen;

or

heteroaryl optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, carboxy, nitro, cyano, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₁₋₆ alkoxy carbonyl, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, C₁₋₆ alkyl optionally substituted by cyano, C₁₋₆ alkoxy carbonyl, or mono-, di-, or tri-halogen, C₁₋₆ alkoxy optionally substituted by mono-, di-, or tri- halogen, and C₁₋₆ alkylthio optionally substituted by mono-, di-, or tri- halogen;

$R^+ R_{III}^1$ (~~Chapter III~~) represents aryl or heteroaryl,

wherein

said aryl and heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxy carbonyl, phenyl (Which phenyl is optionally substituted by halogen, trifluoromethyl, trifluoromethoxy, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆

§Appl. No. 10/575,027
Amdt. dated June 25, 2010
Reply to Office Action of, January 5, 2010

alkoxycarbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆alkyl), amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxycarbonyl, heterocycle, sulfonamide, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, cyano C₁₋₆ alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxycarbonyl or mono-, di-, or tri-halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxycarbonyl or C₁₋₆alkyl), C₁₋₆ alkylthio (which alkylthio is optionally substituted by mono0, di-, or tri- halogen), C₃₋₈ cycloalkyl, and heterocycle;

C₁₋₆ optionally substituted by R¹¹, OR¹², SR¹² or N(R¹²)(R¹³),

wherein

R¹¹ represents aryl or heteroaryl,

wherein

said aryl and heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxycarbonyl, phenyl (which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆alkoxycarbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl), amino, C₃₋₈ cycloalkylamino, or C₁₋₆

alkoxycarbonyl), heterocycle, sulfonamide, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, cyano, C₁₋₆ alkylcarbamoyl, cyano, C₁₋₆ alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxy or mono-, di-, or tri- halogen), C₁₋₆ alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri- halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy or C₁₋₆ alkyl), C₁₋₆ alkylthio (alkylthio is optionally substituted by mono-, di-, or tri- halogen), C₃₋₈ cycloalkyl, and heterocycle;

R¹² represents aryl, heteroaryl, or C₁₋₆ alkyl optionally substituted by aryl or heteroaryl,

wherein

said aryl and heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxy, phenyl (which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl, amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy), heterocycle, sulfonamide, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, cyano, C₁₋₆ alkyl (Which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxy or mono-, di-, or tri- halogen), C₁₋₆ alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri- halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy,

amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl) amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl or C₁₋₆ alkyl), C₁₋₆ alkylthio (which alkylthio is optionally substituted by mono-, di-, or tri-0 halogen), C₃₋₈cycloalkyl, and heterocycle;
and

R¹³ represents hydrogen or C₁₋₆ alkyl;

or

C₃₋₈ cycloalkyl optionally fused by aryl,

wherein

said aryl is optionally substituted with one or more substituents selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxy carbonyl, phenyl (which phenyl is optionally substituted by halogen nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl), amino C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl), heterocycle, sulfonamide, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, cyano, C₁₋₆ alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxy carbonyl or mono-, di-, or tri- halogen), C₁₋₆ alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri- halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl or C₁₋₆ alkyl), C₁₋₆

§Appl. No. 10/575,027
Amdt. dated June 25, 2010
Reply to Office Action of, January 5, 2010

alkylthio (alkylthio is optionally substituted by mono-, di-, or tri- halogen), C₃₋₈ cycloalkyl, and heterocycle,

m represents 0, , 2, or 3;

p represents 0 or 1;

-X- represents a bond, -O- or N(R¹)- (wherein R¹ is hydrogen or C₁₋₆ alkyl);

with the proviso that when m is 0, -X- represents a bond,


R represents aryl or heteroaryl,

~~Wherein~~ wherein said aryl and heteroaryl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxy carbonyl, phenyl (which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl, sulfonamide, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, cyano, C₁₋₆ alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxy carbonyl or mono-, di-, or tri- halogen), C₁₋₆ alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri- halogen,), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl or C₁₋₆ alkyl), C₁₋₆

§Appl. No. 10/575,027
Amdt. dated June 25, 2010
Reply to Office Action of, January 5, 2010

alkylthio (which alkylthio is optionally substituted by mono-, di-, or tri-halogen), C₃₋₈ cycloalkyl, and heterocycle.

2. (Original) Compound of ~~formula (A) according to claim 1~~, with the formula (I), their tautomeric and stereoisomeric form, and salts thereof:



wherein

n represents an integer of 0 to 6;

Q_1 and Q_4 independently represent direct bond or methylene;

Chemical bond between Q_2 ---- Q_3 is selected from the group consisting of a single bond and a double bond;

when Q_2 ---- Q_3 is a single bond, Q_2 represents CHR^2 , or CO , and Q_3 represents CHR^3 ,

Q_2 ---- Q_3 is a double bond, Q_2 represents CR^2 and Q_3 represents CR^3 ;

wherein

R^2 represents hydrogen, hydroxy, C_{1-6} alkoxy or C_{1-6} alkanoyloxy;
 R^3 represents hydrogen, hydroxy, C_{1-6} alkoxy or C_{1-6} alkanoyloxy or C_{1-6} alkyl optionally substituted by hydroxy, C_{1-6} alkoxy or C_{1-6} alkanoyloxy;

with the proviso that Q_1 and Q_4 can not be direct bond at the same time;

R^2 and R^3 cannot be hydrogen at the same time;

when Q_1 and Q_4 are both methylene and R^3 is hydroxy, R^2 is hydroxyl, C_{1-6} alkoxy or C_{1-6} alkanoyloxy;



when Q_1 is direct bond, R^2 hydroxy, C_{1-6} alkoxy or C_{1-6} alkanoyloxy; and
when Q_4 is direct bond, R^2 is hydrogen, C_{1-6} alkoxy or C_{1-6} alkanoyloxy;

and

R^4 represents aryl optionally having one or two substituents selected from the group consisting of halogen, hydroxy, C_{1-6} alkylamino, di(C_{1-6} alkyl)amino, C_{3-8} cycloalkylamino, C_{1-6} alkoxy carbonyl, phenyl, benzyl, sulfonamide, C_{1-6} alkanoyl, C_{1-6} alkanoylamino, carbamoyl, C_{1-6} alkylcarbamoyl, cyano, C_{1-6} alkyl optionally substituted by cyano, C_{1-6} alkoxy carbonyl, or mono-, di-, or tri- halogen, C_{1-6} alkoxy optionally substituted by mono-, di-, or tri- halogen, phenoxy optionally substituted by halogen or C_{1-6} alkyl, and C_{1-6} alkylthio optionally substituted by mono-, di-, or tri- halogen.

§Appl. No. 10/575,027
 Amdt. dated June 25, 2010
 Reply to Office Action of, January 5, 2010

3. (Currently Amended) Compound of formula (A) according to claim 1,
 with of the formula (I) (II), their tautomeric and stereoisomeric form, and salts thereof:



wherein

n represents an integer of 0 to 6; and

R¹ R_{II} represents C₃₋₈cycloalkyl optionally fused by aryl ar_I,

wherein

said aryl is optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, carboxy, nitro, cyano, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, C₁₋₆ alkyl optionally substituted by cyano, C₁₋₆ alkoxycarbonyl, or mono-, di-, or tri- halogen, C₁₋₆ alkoxy optionally substituted by mono-di-, or tri- halogen and C₁₋₆ alkylthio optionally substituted by mono-, di-, or tri- halogen;

phenyl substituted by heteroaryl, or heteroaryloxy,

wherein

said Heteroaryl and heteroaryloxy are optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, carboxy, nitro, cyano, amino, C₁₋₆ alkylamino, di(C₁₋₆alkyl)amino, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, C₁₋₆ alkyl optionally substituted by cyano, C₁₋₆ alkoxycarbonyl, or mono-, di-, or tri-halogen, C₁₋₆ alkoxy optionally substituted by mono-, di-, or tri-halogen and C₁₋₆ alkylthio optionally substituted by mono-, di-, or tri-halogen;

phenyl fused with heteroaryl, or heterocyclyl,

wherein

said heteroaryl is optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, carboxy, nitro, cyano, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkanoyl, C₁₋₆


§Appl. No. 10/575,027
Amdt. dated June 25, 2010
Reply to Office Action of, January 5, 2010

alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, C₁₋₆ alkyl optionally substituted by cyano, C₁₋₆ alkoxy, carbonyl, or mono-, di-, or tri-halogen, C₁₋₆ alkoxy optionally substituted by mono-, di-, or tri-, halogen and C₁₋₆ alkylthio optionally substituted by mono-, di-, or tri- halogen;


or

heteroaryl optionally substituted with one or more substituents selected from the halogen, hydroxy, carboxy, nitro, cyano, amino, phenyl, benzyl, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₁₋₆ alkoxy, carbonyl, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, C₁₋₆ alkyl optionally substituted by cyano, C₁₋₆ alkoxy, carbonyl, or mono-, di-, or tri-halogen, C₁₋₆ alkoxy, optionally substituted by mono-, di-, or tri- halogen and C₁₋₆ alkylthio optionally substituted by mono-, di-, or tri- halogen.

4. (Currently Amended) Compound of ~~formula (A)~~ according to claim 1, of with the formula ~~(I)~~ (III), their tautomeric and stereoisomeric form, and salts thereof:



§Appl. No. 10/575,027
 Amdt. dated June 25, 2010
 Reply to Office Action of, January 5, 2010



R^1 R_{III}^1 represents aryl or heteroaryl,

wherein

said aryl and heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxy carbonyl, phenyl (which phenyl is optionally substituted by halogen, trifluoromethyl, trifluoromethoxy, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl), sulfonamide, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, cyano, C₁₋₆ alkyl (which alkyl is optionally substituted by cyano, C₁₋₆ alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxy carbonyl or mono-, di-, or tri-halogen), C₁₋₆ alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri-halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxy carbonyl or C₁₋₆ alkyl), C₁₋₆

alkylthio (which alkylthio is optionally substituted by mono-, di-, or tri-halogen), C₃₋₈ cycloalkyl, and heterocycle;

C₁₋₆ alkyl optionally substituted by R¹¹, OR¹², SR¹² or N(R¹²)(R¹³),

wherein

R¹¹ represents aryl or heteroaryl,

wherein

said aryl and heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxy carbonyl, phenyl (which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl), sulfonamide, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, cyano, C₁₋₆ alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxy carbonyl or mono-, di-, tri-halogen), C₁₋₆ alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri-halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino C₁₋₆ alkylamino, di(C₁₋₆alkylamiono, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxy carbonyl or C₁₋₆ alkyl), C₁₋₆ alkylthio (which alkylthio is optionally substituted by mono-, di-, or tri-halogen), C₃₋₈ cycloalkyl, and heterocycle;

R¹² represents aryl, heteroaryl, or C₁₋₆ alkyl optionally substituted by aryl or heteroaryl,

wherein

said aryl and heteroaryl are optionally substituted with one or more substituents selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxy carbonyl, phenyl (which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl), sulfonamide, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, cyano, C₁₋₆ alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxy carbonyl or mono-, di-, or tri- halogen), C₁₋₆ alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri- halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxy carbonyl or C₁₋₆ alkyl), C₁₋₆ alkylthio (which alkylthio is optionally substituted by mono-, di-, or tri- halogen), C₃₋₈ cycloalkyl, and heterocycle; and

R¹³ represents hydrogen, or C₁₋₆ alkyl;

or

C₃₋₈ cycloalkyl optionally fused by aryl,

wherein

said aryl is optionally substituted with one or more substituents from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxy carbonyl, phenyl (which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, or C₁₋₆ alkoxy carbonyl), sulfonamide, C₁₋₆ alkanoyl, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkylcarbamoyl, cyano, C₁₋₆ alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C₁₋₆ alkoxy carbonyl or mono-, di-, or tri- halogen), C₁₋₆ alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri- halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C₁₋₆ alkylamino, di(C₁₋₆ alkyl)amino, C₃₋₈ cycloalkylamino, C₁₋₆ alkoxy carbonyl or C₁₋₆ alkyl), C₁₋₆ alkylthio (which alkylthio is optionally substituted by mono-, di-, or tri- halogen), C₃₋₈ cycloalkyl, and heterocycle.

5. (Cancelled)

6. (Original) A medicament comprising the compound of the formula (A), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1 as an active ingredient.

§Appl. No. 10/575,027
Amdt. dated June 25, 2010
Reply to Office Action of, January 5, 2010

7. (Original) The medicament as claimed in claim 6, further comprising one or more pharmaceutically acceptable excipients.

8. (Currently Amended) The medicament as claimed in claim 6, effective as ~~wherein said compound of the formula (A), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof~~ is a VR1 antagonist.

9. (Original) The medicament as claimed in claim 6 for the treatment and/or prevention of an urological disorder or disease.

10. (Currently Amended) The medicament as claimed in claim 9, wherein said urological disorder or disease is detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor ~~overactivity~~ overactivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms.

11. (Original) The medicament as claimed in claim 6 for the treatment and/or prevention of pain.

12. (Original) The medicament as claimed in claim 11, wherein said pain is chronic pain neuropathic pain, postoperative pain, or rheumatoid arthritic pain.

13. (Original) The medicament as claimed in claim 6 for the treatment and/or prevention of a disorder or disease related to pain.

14. (Currently Amended) The medicament as claimed in claim 13, wherein said disorder or disease ~~related~~ related to pain is neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, or stroke.

§Appl. No. 10/575,027
Amdt. dated June 25, 2010
Reply to Office Action of, January 5, 2010

15. (Original) The medicament as claimed in claim 6 for the treatment and/or prevention of an inflammatory disorder or disease.
16. (Original) The medicament as claimed in claim 15, wherein said inflammatory disorder or disease is asthma or COPD.
17. (Currently Amended) A method of using ~~Use of~~ compounds according to claim 1, comprising ~~for~~ manufacturing a medicament for the treatment and/or prevention of an urological disorder or disease.
18. (Currently Amended) A method of using ~~Use of~~ compounds according to claim 1, comprising ~~for~~ manufacturing a medicament for the treatment and/or prevention of pain.
19. (Currently Amended) A method of using ~~Use of~~ compounds according to claim 1, comprising manufacturing a medicament for the treatment and/or prevention of an inflammatory disorder or disease.
20. (Original) Process for controlling an urological disorder or disease in humans and animals by administration of a VR1-antagonistically effective amount of at least one compound according to claim 1.
21. (Original) Process for controlling pain in humans and animals by administration of a VR1-antagonistically effective amount of at least one compound according to claim 1.

§Appl. No. 10/575,027
Amdt. dated June 25, 2010
Reply to Office Action of, January 5, 2010

22. (Original) Process for controlling an inflammatory disorder of disease in humans and animals by administration of a VR1-antagonistically effective amount of at least one compound according to claim 1.